Figure 2From: Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjectsMean sputum inflammatory cells (± SEM) at baseline before treatment with roflumilast (solid bars) or placebo (open bars), after 13 days' treatment, and 7 h and 24 h after allergen challenge. Roflumilast significantly inhibited the allergen-induced influx of sputum eosinophils, neutrophils and metachromatic cells (p < 0.05).Back to article page